AN2 Therapeutics (ANTX) Net Equity Issued and Repurchased (2021 - 2025)

AN2 Therapeutics (ANTX) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $48000.0 in Q3 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 108.7% year-over-year to $48000.0 in Q3 2025; TTM through Dec 2025 was $86000.0, a 41.5% decrease from a year earlier, with the FY2025 full-year figure at $86000.0, down 41.5% from the prior year.
• Net Equity Issued and Repurchased for Q3 2025 stood at $48000.0, up from $38000.0 in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for ANTX reached as high as $79.7 million in Q1 2021 and fell as low as -$4.5 million in Q4 2022.
• Historically, Net Equity Issued and Repurchased has averaged $11.8 million across 5 years, with a median of $86000.0 in 2024.
• Across the five-year window, Net Equity Issued and Repurchased soared 516.31% in 2023 and tumbled 69.35% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $79.7 million in 2021, then plunged by 105.64% to -$4.5 million in 2022, then surged by 516.31% to $18.7 million in 2023, then tumbled by 99.88% to $23000.0 in 2024, then surged by 108.7% to $48000.0 in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $48000.0 in Q3 2025, $38000.0 in Q1 2025, and $23000.0 in Q3 2024.